Artal Group’s Alto Neuroscience ANRO Stock Holding History

Artal Group’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-350,000	Closed	-$3.74M	–	100
2024 Q2	$3.74M	Hold	350,000	–	–	0.1%	63
2024 Q1	$5.37M	Buy	+350,000	New	+$5.48M	0.14%	60

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Artal Group's ANRO Position: Q3 2024 in Review

Artal Group sold out of Alto Neuroscience (ANRO) in Q3 2024, closing a stake of 350,000 shares — an estimated $3.74M sold.

Artal Group first reported a position in ANRO in Q1 2024 and held it in 2 quarters. The position peaked at $5.37M in Q1 2024. 75 funds tracked by Wall St. Rank hold ANRO as of Q3 2024.

Artal Group reported no remaining Alto Neuroscience position as of Q3 2024 after selling out during the quarter.
Artal Group sold 350,000 Alto Neuroscience shares in Q3 2024, an estimated $3.74M.
Artal Group first reported a position in Alto Neuroscience in Q1 2024 and held it in 2 quarters.
Artal Group's Alto Neuroscience position peaked at $5.37M in Q1 2024.
75 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.